Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis

PLoS Neglected Tropical Diseases

Volumn 4, Issue 10, 2010, Pages

  Wauquier, Nadia ^a   Becquart, Pierre ^a,b   Padilla, Cindy ^a   Baize, Sylvain ^c   Leroy, Eric M ^a,b  

^a CENTRE INTERNATIONAL DE RECHERCHES MÉDICALES DE FRANCEVILLE   (Gabon)

^b Aix Marseille University IRD 190 Inserm 1207   (France)

^c Institut Pasteur   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; COLONY STIMULATING FACTOR 1; CXCL1 CHEMOKINE; EOTAXIN; FAS ANTIGEN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GROWTH FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 16; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; RANTES; STROMAL CELL DERIVED FACTOR 1; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ADULT; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEMOCRATIC REPUBLIC CONGO; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; EPIDEMIC; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PHENOTYPE; SURVIVOR; T LYMPHOCYTE;

EID: 78449261317     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000837     Document Type: Article

References (73)

1. Hoenen T, Groseth A, Falzarano D, Feldmann H (2006) Ebola virus: unravelling pathogenesis to combat a deadly disease. Trends Mol Med 12: 206-215.
2. Sanchez A, Geisbert TW, Feldmann H (2007) Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM, eds. Fields virology. Philadelphia: Lippincott Williams and Williams. pp 1409-1448.
3. Feldmann H, Geisbert TW, Jahrling PB, Klenk HD, Netesov SV, et al. (2005) Filoviridae. In: Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA, eds. Virus taxonomy: VIIIth report of the international committee on taxonomy of viruses. London, UK: Elsevier Academic Press. pp 645-653.
4. Johnson KM (1978) Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ 56: 271-293.
5. Khan AS, Tshioko FK, Heymann DL, Le Guenno B, Nabeth P, et al. (1999) The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. J Infect Dis 179: S76-S86.
6. Georges AJ, Leroy EM, Renaut AA, Tevi Benissan C, Nabias RJ, et al. (1999) Ebola hemorrhagic fever outbreaks in Gabon, 1994-1997: Epidemiologic and Health control issues. J Infect Dis 179: S65-S75.
7. Leroy EM, Rouquet P, Formenty P, Souquière S, Kilbourne A, et al. (2004) Multiple Ebola virus transmission events and rapid decline of central african wildlife. Science 303: 387-390.
8. Formenty P, Leroy EM, Epelboin A, Libama F, Lenzi M, et al. (2006) Detection of Ebola virus in oral fluid specimens during outbreaks of Ebola virus hemorrhagic fever in the Republic of Congo. Clin Infect Dis 42: 1521-1526.
9. Wittmann TJ, Biek R, Hassanin A, Rouquet P, Reed P, et al. (2007) Isolates of Zaire ebolavirus from wild apes reveal genetic lineage and recombinants. Proc Natl Acad Sci U S A 104: 17123-17127.
10. Smith DIH (1978) Ebola haemorrhagic fever in Sudan, 1976. Bull World Health Organ 56: 247-270.
11. Baron RC, McCormick JB, Zubeir OA (1983) Ebola virus disease in southern Sudan: hospital dissemination and intrafamilial spread. Bull World Health Organ 61: 997-1003.
12. World Health Organization (2004) Ebola haemorrhagic fever in south Sudan - update. Wkly Epidemiol Rec 79: 253.
13. Centers for Disease Control (2001) Ebola outbreak in Uganda. Morb Mortal Wkly Rep 50: 73-77.
14. Okware SI, Omaswa FG, Zaramba S, Opio A, Lutwama JJ, et al. (2002) An outbreak of Ebola in Uganda. Trop Med Int Health 7: 1068-1075.
15. Le Guenno B, Formenty P, Wyers M, Gounon P, Walker F, et al. (1995) Isolation and partial characterisation of a new strain of Ebola. The Lancet 345: 1271-1274.
16. Formenty P, Hatz C, Le Guenno B, Stoll A, Rogenmoser P, et al. (1999) Human infection due to Ebola virus, subtype côte d'ivoire: clinical and biologic presentation. J Infect Dis 179: S48-S53.
17. Towner JS, Sealy TK, Khristova ML, Albarino CG, Conlan S, et al. (2008) Newly discovered ebola virus associated with hemorrhagic Fever outbreak in Uganda. PLoS Pathog 4: e1000212.
18. Jahrling PB, Geisbert TW, Dalgard DW, Johnson ED, Ksiazek TG, et al. (1990) Preliminary report: isolation of Ebola virus from monkeys imported to USA. Lancet 335: 502-505.
19. Rollin PE, Williams RJ, Bressler DS, Pearson S, Cottingham M, et al. (1999) Ebola (subtype Reston) virus among quarantined nonhuman primates recently imported from the Philippines to the United States. J Infect Dis 179: S108-S114.
20. Barrette RW, Metwally SA, Rowland JM, Xu L, Zaki SR, et al. (2009) Discovery of swine as a host for the Reston ebolavirus. Science 325: 204-206.
21. Schnittler HJ, Mahner F, Drenckhahn D, Klenk HD, Feldmann H (1993) Replication of Marburg virus in human endothelial cells. J Clin Invest 91: 1301-1309.
22. Feldmann H, Bugany H, Mahner F, Klenk HD, Drenckhahn D, et al. (1996) Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages. J Clin Invest 70: 2208-2214.
23. Ströher U, West E, Bugany H, Klenk H-D, Schnittler H-J, et al. (2001) Infection and activation of monocytes by Marburg and Ebola viruses. J Virol 75: 11025-11033.
24. Geisbert TW, Hensley L, Larsen T, Young HA, Reed DS, et al. (2003) Pathogenesis of Ebola Hemorrhagic fever in cynomolgus macaques. Am J Pathol 163: 2347-2370.
25. Bosio CM, Aman MJ, Grogan C, Hogan R, Ruthel G, et al. (2003) Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis 188: 1630-1638.
26. Bray M, Hatfill S, Hensley L, Huggins JW (2001) Haematological, biochemical and coagulation changes in mice, guinea pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. J Comp Path 125: 243-253.
27. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, et al. (2003) Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 188: 1618-1629.
28. Bray M, Mahanty S (2003) Ebola hemorrhagic fever and septic shock. J Infect Dis 188: 1613-1617.
29. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Larsen T, et al. (2003) Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol 163: 2371-2382.
30. Geisbert TW, Hensley LE, Gibb TR, Steele KE, Jaax NK, et al. (2000) Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest 80: 171-186.
31. Gibb TR, Bray M, Geisbert TW, Steele KE, Kell WM, et al. (2001) Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice. J Comp Path 125: 233-242.
32. Hensley L, Young HA, Jahrling PB, Geisbert TW (2002) Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Letters 80: 169-179.
33. Reed DS, Hensley LE, Geisbert JB, Jahrling PB, Geisbert TW (2004) Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic Fever in cynomolgus macaques. Viral Immunol 17: 390-400.
34. Warfield KL, Perkins JG, Swenson DL, Deal EM, Bosio CM, et al. (2004) Role of natural killer cells in innate protection against lethal ebola virus infection. J Exp Med 200: 169-179.
35. Rubins KH, Hensley LE, Wahl-Jensen V, Daddario DiCaprio KM, Young HA, et al. (2007) The temporal program of peripheral blood gene expression in the response of nonhuman primates to Ebola hemorrhagic fever. Genome Biol 8: R174.
36. Ryabchikova EI (1999) Pathophysiology of filovirus infections. In: Klenk H-D, ed. Current topics in microbiology and immunology: Marburg and Ebola viruses. Berlin: Springer-Verlag. pp 145-173.
37. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J (1998) A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 179: 248-258.
38. Connolly BM, Steele KE, Davis KJ, Geisbert TW, Kell WM, et al. (1999) Pathogenesis of experimental Ebola virus infection in Guinea pigs. J Infect Dis 179: S203-S217.
39. Bowen ETW, Platt GS, Simpson DIH, McArdell LB, Raymond RT (1978) Ebola haemorrhagic fever: Experimental infection of monkeys. Trans R Soc Trop Med Hyg 72: 188-191.
40. Jaax NK, Davis KJ, Geisbert TJ, Vogel P, Jaax GP, et al. (1996) Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. Arch Pathol Lab Med 120: 140-155.
41. Fisher-Hoch SP, Brammer TL, Trappier SG, Hutwagner LC, Farrar BB, et al. (1992) Pathogenic potential of filoviruses: Role of geographic origin of primate host and virus strain. J Infect Dis 166: 753-763.
42. Fisher-Hoch SP, Platt GS, Neild GH, Southree T, Baskerville A, et al. (1985) Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola). J Infect Dis 152: 887-894.
43. Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, et al. (2002) Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 8: 503-507.
44. Villinger F, Rollin PE, Brar SS, Chikkala NF, Winter J, et al. (1999) Markedly elevated levels of interferon (IFN)- c, IFN-a, Interleukin (IL)-2, IL-10, and Tumor Necrosis Factor-a associated with fatal Ebola virus infection. J Infect Dis 179: S188-191.
45. Baize S, Leroy EM, Georges-Courbot M-C, Capron M, Lansoud-Soukate J, et al. (1999) Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nature Med 5: 1-5.
46. Leroy EM, Baize S, Volchkov VE, Fisher-Hoch SP, Georges-Courbot M-C, et al. (2000) Human asymptomatic Ebola infection and strong inflammatory response. Lancet 355: 2210-2215.
47. Baize S, Leroy EM, Georges AJ, Georges-Courbot M-C, Capron M, et al. (2001) Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol 128: 163-168.
48. Leroy EM, Baize S, Debré P, Lansoud-Soukate J, Mavoungou E (2001) Early immune responses accompanying human asymptomatic Ebola infections. Clin Exp Immunol 124: 453-460.
49. Becquart P, Wauquier N, Mahlakoiv T, Nkoghe D, Padilla C, et al. (2010) High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon. PLoS One 5: e9126.
50. Harcourt BH, Sanchez A, Offermann MK (1999) Ebola virus selectively inhibits responses to interferons, but not to interleukin-1beta, in endothelial cells. J Virol 73: 3491-3496.
51. Gupta M, Mahanty S, Ahmed R, Rollin PE (2001) Monocyte-derived human macrophage and peripheral blood mononuclear cells infected with Ebola virus secrete MIP-1a and TNF-a and inhibit poly-IC-induced IFN-a in vitro. Virology 284: 20-25.
52. Mahanty S, Hutchinson K, Agarwal S, McRae M, Rollin PE, et al. (2003) Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol 170: 2797-2801.
53. Basler CF, Wang X, Muhlberger E, Volchkov V, Paragas J, et al. (2000) The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci U S A 97: 12289-12294.
54. Kash JC, Muhlberger E, Carter V, Grosch M, Perwitasari O, et al. (2006) Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence. J Virol 80: 3009-3020.
55. Hartman AL, Ling L, Nichol ST, Hibberd ML (2008) Whole-genome expression profiling reveals that inhibition of host innate immune response pathways by Ebola virus can be reversed by a single amino acid change in the VP35 protein. J Virol 82: 5348-5358.
56. Leung DW, Ginder ND, Fulton DB, Nix J, Basler CF, et al. (2009) Structure of the Ebola VP35 interferon inhibitory domain. Proc Natl Acad Sci U S A 106: 411-416.
57. Basler CF, Amarasinghe GK (2009) Evasion of interferon responses by Ebola and Marburg viruses. J Interferon Cytokine Res 29: 511-520.
58. Reid SP, Leung LW, Hartman AL, Martinez O, Shaw ML, et al. (2006) Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol 80: 5156-5167.
59. Reid SP, Valmas C, Martinez O, Sanchez A, Basler CF (2007) Ebola virus VP24 proteins inhibit the interaction of NP1-1 subfamily karyopherin alpha proteins with activated STAT1. J Virol 81: 13469-13477.
60. Basler CF, Mikulasova A, Martinez-Sobrido L, Paragas J, Muhlberger E, et al. (2003) The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol 77: 7945-7956.
61. Hartman AL, Towner JS, Nichol ST (2004) A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus. Virology 328: 177-184.
62. Cardenas WB, Loo YM, Gale M, Jr., Hartman AL, Kimberlin CR, et al. (2006) Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J Virol 80: 5168-5178.
63. Hartman AL, Bird BH, Towner JS, Antoniadou ZA, Zaki SR, et al. (2008) Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of ebola virus. J Virol 82: 2699-2704.
64. Prins KC, Cardenas WB, Basler CF (2009) Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1, J Virol 83: 3069-3077.
65. Chang TH, Kubota T, Matsuoka M, Jones S, Bradfute SB, et al. (2009) Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathog 5: e1000493.
66. Feng Z, Cerveny M, Yan Z, He B (2007) The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR. J Virol 81: 182-192.
67. Haasnoot J, de Vries W, Geutjes EJ, Prins M, de Haan P, et al. (2007) The Ebola virus VP35 protein is a suppressor of RNA silencing. PLoS Pathog 3: e86.
68. Baize S, Leroy EM, Mavoungou E, Fisher-Hoch SP (2000) Apoptosis in fatal Ebola infection. Does the virus toll the bell for the immune system? Apoptosis 5: 5-7.
69. Bradfute SB, Braun DR, Shamblin JD, Geisbert JB, Paragas J, et al. (2007) Lymphocyte death in a mouse model of Ebola virus infection. J Infect Dis 196 Suppl 2: S296-304.
70. Bradfute SB, Warfield KL, Bavari S (2008) Functional CD8+ T cell responses in lethal Ebola virus infection. J Immunol 180: 4058-4066.
71. Gupta M, Spiropoulou C, Rollin PE (2007) Ebola virus infection of human PBMCs causes massive death of macrophages, CD4 and CD8 T cell subpopulations in vitro. Virology 364: 45-54.
72. Volchkov VE, Blinov VM, Netesov SV (1992) The envelope glycoprotein of Ebola virus contains an immunosuppressive-like domain similar to oncogenic retroviruses. FEBS 305: 181-184.
73. Yaddanapudi K, Palacios G, Towner JS, Chen I, Sariol CA, et al. (2006) Implication of a retrovirus-like glycoprotein peptide in the immunopathogenesis of Ebola and Marburg viruses. FASEB J 20: 2519-2530.